Literature DB >> 24463400

Single-domain antibody-based ligands for immunoaffinity separation of recombinant human lactoferrin from the goat lactoferrin of transgenic goat milk.

S V Tillib1, M E Privezentseva2, T I Ivanova2, L F Vasilev2, G A Efimov3, Y G Gursky2, G P Georgiev2, I L Goldman2, E R Sadchikova2.   

Abstract

Single-domain antibody generation technology was applied to make new Sepharose-bound ligands for affinity separation of closely related proteins, such as human and goat lactoferrin. We generated recombinant antibodies that can selectively bind/recognize only lactoferrins having amino acid sequences identical to that of human natural lactoferrin (anti-hLF Ab). Selected and purified histidine-tagged single-domain antibodies were used as ligands, and different lactoferrins were used as analytes in the kinetics analysis of lactoferrin binding to captured anti-hLF Abs using the Bio-Rad ProteOn XPR36 protein interaction array system. The data obtained were consistent with a 1:1 binding model with very high affinity, practically equal in the case of hLF and rec-hLF (calculated KD varied from 0.43nM to 3.7nM). Interaction of captured fsdAbs with goat LF was significantly weaker and not detectable under the same analysis conditions. We demonstrated the high efficiency of the recombinant human lactoferrin purification from goat lactoferrin and other proteins using the obtained single domain antibody-based affinity ligands. We believe this approach can be used for the generation of single-domain antibody-based affinity media for the efficient separation/purification of a wide spectrum of other highly homologous proteins.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Immunoaffinity chromatography; Recombinant human lactoferrin; Separation of homologous proteins; Single-domain antibody

Mesh:

Substances:

Year:  2014        PMID: 24463400     DOI: 10.1016/j.jchromb.2013.12.034

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  4 in total

Review 1.  The transgenic animal platform for biopharmaceutical production.

Authors:  L R Bertolini; H Meade; C R Lazzarotto; L T Martins; K C Tavares; M Bertolini; J D Murray
Journal:  Transgenic Res       Date:  2016-01-28       Impact factor: 2.788

2.  Cell-type-restricted anti-cytokine therapy: TNF inhibition from one pathogenic source.

Authors:  Grigory A Efimov; Andrei A Kruglov; Zoya V Khlopchatnikova; Fedor N Rozov; Vladislav V Mokhonov; Stefan Rose-John; Jürgen Scheller; Siamon Gordon; Martin Stacey; Marina S Drutskaya; Sergei V Tillib; Sergei A Nedospasov
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-02       Impact factor: 11.205

3.  Genetic Passive Immunization with Adenoviral Vector Expressing Chimeric Nanobody-Fc Molecules as Therapy for Genital Infection Caused by Mycoplasma hominis.

Authors:  Daria A Burmistrova; Sergey V Tillib; Dmitry V Shcheblyakov; Inna V Dolzhikova; Dmitry N Shcherbinin; Olga V Zubkova; Tatiana I Ivanova; Amir I Tukhvatulin; Maxim M Shmarov; Denis Y Logunov; Boris S Naroditsky; Aleksandr L Gintsburg
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

4.  High-Affinity Single-Domain Antibodies for Analyzing Human Apo- and Holo-Transferrin.

Authors:  S V Tillib; O S Goryainova; A M Sachko; T I Ivanova
Journal:  Acta Naturae       Date:  2022 Apr-Jun       Impact factor: 2.204

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.